Ibotta Inc. (IBTA) shares plunged 34.6% in pre-market trading following the release of disappointing second-quarter results and a downbeat outlook for the third quarter. Several financial institutions have adjusted their price targets and ratings for Ibotta, with Citi lowering its target from $125 to $95 but maintaining a buy rating, Evercore reducing its target to $38 from $65 and downgrading to in-line from outperform, Needham cutting its target to $33 while keeping a buy rating, Wells Fargo lowering its target to $30 and downgrading to equal weight from overweight, and Goldman Sachs reducing its target to $30 and downgrading to neutral from buy. UBS has also made adjustments, though specific details were not provided. In the broader market, Barclays initiated coverage on Smartsheet (SDGR) with an overweight rating and a $25 price target, Morgan Stanley resumed coverage on Rocket Companies (RKT) with an equal weight rating and a $16 target, and HSBC upgraded DLocal (DLO) to buy from hold, raising its target to $15 from $11.50. Other analyst moves included HC Wainwright lowering BioNTech's (BNTX) target to $136, Scotiabank upgrading BP to sector outperform with a target of $42, Piper Sandler lowering Black Stone Minerals to $13, and Goldman Sachs initiating coverage on Cal-Maine Foods (CALM) at neutral with a $110 target. Additional notable changes were seen across various sectors, including energy, technology, and pharmaceuticals, with targets and ratings adjusted by firms such as Piper Sandler, Stifel, Rosenblatt, JPMorgan, and Mizuho.